ArticleImmunity2024
Convergent evolution and targeting of diverse E2 epitopes by human broadly neutralizing antibodies are associated with HCV clearance.
Open access · greenAbstract readComment
In one paragraph
Article in Immunity, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
6.3field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 17 citations in OpenAlex.
- Structural and genetic signatures of two classes of HCV E2 neutralizing face antibodies from non-human primates immunized with a recombinant E1E2.NPJ vaccines · 2026Article
- Targeted Removal of HCV E2 N2 N-Glycan Is Associated with Improved Immune Responses in Mice.Biomolecules · 2026Article
- mAbClust with AlphaFold 3 avoids hallucinations to define a quaternary broadly neutralizing HCV epitope.bioRxiv : the preprint server for biology · 2026Article
- Antibody responses to a highly conserved peptide in HCV E2 protein correlate with chronicity or spontaneous clearance of HCV infection.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- The Use of Human Liver Chimeric Mice to Study Hepatitis C Virus Antibody Escape: Implications for Vaccine Development.Cellular and molecular gastroenterology and hepatology · 2026Article
- Broadly Neutralizing Antibody Characteristics in Hepatitis C Virus Infection and Implications for Vaccine Design.Vaccines · 2025Review
- Cryo-EM structures of HCV E2 glycoprotein bound to neutralizing and non-neutralizing antibodies determined using bivalent Fabs as fiducial markers.Communications biology · 2025Article
- Review
- Bispecific antibodies against the hepatitis C virus E1E2 envelope glycoprotein.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Selection and characterization of a broadly neutralizing class of HCV anti-E2 VH1-69 antibodies.PLoS pathogens · 2025Article
- Coordinated expansion of memory T follicular helper and B cells mediates spontaneous clearance of HCV reinfection.Frontiers in immunology · 2024Article
Corrections and comments
- Comment on
Authors and funding
14 authors at 4 institutions in 1 country.
Clinton O OgegaDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Nicole E SkinnerDivision of Infectious Diseases, Department of Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA; Center for Vaccines and Immunity, The Abigail Wexner Research Institute, Nationwide Children's Hospital, Columbus, OH, USA.
Marta V SchoenleDepartment of Microbiology and Immunology, Cornell University, Ithaca, NY, USA.
Xander E WilcoxDepartment of Microbiology and Immunology, Cornell University, Ithaca, NY, USA.
Nicole FrumentoDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Desiree A WrightDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Harry T PaulDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Ariadne Sinnis-BourozikasDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Kaitlyn E ClarkDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Alexis FigueroaDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Pamela J BjorkmanDivision of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.
Stuart C RayDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA; Department of Pharmacology and Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Andrew I FlyakDepartment of Microbiology and Immunology, Cornell University, Ithaca, NY, USA. Electronic address: andrew.flyak@cornell.edu.
Justin R BaileyDivision of Infectious Diseases, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. Electronic address: jbailey7@jhmi.edu.
Johns Hopkins University · USCornell University · USCalifornia Institute of Technology · USNationwide Children's Hospital · US
Funding
X-ray Absorption Spectroscopy (XAS) pp.711-759P41GM103393 · NIGMS · STANFORD UNIVERSITY · PI HODGSON, KEITH O · 2012 to 2019
$30.6MThe development and pre-clinical assessment of novel HCV vaccines to generate T and B cell immunityU19AI159822 · NIAID · JOHNS HOPKINS UNIVERSITY · PI BAILEY, JUSTIN RICHARD · 2021 to 2025
$14.4MRESEARCH TRAINING IN MICROBIAL DISEASEST32AI007291 · NIAID · JOHNS HOPKINS UNIVERSITY · PI JOEL N BLANKSON, Sara Elizabeth Cosgrove · 1986 to 2026
$9.1MMolecular and structural characterization of broadly neutralizing anti-HCV antibodiesR01AI127469 · NIAID · JOHNS HOPKINS UNIVERSITY · PI Justin Richard Bailey · 2017 to 2026
$6.8MHost-Microbe Interactions that Determine Host Traits and DiseaseT32AI145821 · NIAID · CORNELL UNIVERSITY · PI LAZZARO, BRIAN · 2020 to 2024
$1.9MImmunization strategies to elicit broadly neutralizing antibodies against HCVR00AI153465 · NIAID · CORNELL UNIVERSITY · PI FLYAK, ANDREW I · 2022 to 2023
$498kHigh-throughput label-free detection system for biomolecular interaction analysisS10OD032273 · OD · CORNELL UNIVERSITY · PI DELISA, MATTHEW P · 2022 to 2022
$350kImmunization strategies to elicit broadly neutralizing antibodies against HCVK99AI153465 · NIAID · CALIFORNIA INSTITUTE OF TECHNOLOGY · PI FLYAK, ANDREW I · 2020 to 2021
$259kNIAID NIH HHS K99 AI153465NIAID NIH HHS R00 AI153465NIAID NIH HHS R01 AI127469NIAID NIH HHS T32 AI145821NIAID NIH HHS U19 AI159822NIGMS NIH HHS P41 GM103393NIH HHS S10 OD032273
Abstract
The early appearance of broadly neutralizing antibodies (bNAbs) in serum is associated with spontaneous hepatitis C virus (HCV) clearance, but to date, the majority of bNAbs have been isolated from chronically infected donors. Most of these bNAbs use the V
Indexed as
HepacivirusHepatitis CAntibodies, NeutralizingBroadly Neutralizing AntibodiesEpitopesHumansViral Envelope ProteinsAntibodies, NeutralizingBroadly Neutralizing AntibodiesEpitopesViral Envelope Proteinsantibody evolutionB cellsBCR sequencingbroadly neutralizing antibodiesHCVhepatitis C virusmonoclonal antibodiesneutralizing epitopesvaccine
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.